Lifirafenib (BGB-283) is primarily used in the field of oncology as a targeted therapy for certain types of cancer. It functions as a dual inhibitor of BRAF and EGFR kinases, which are often implicated in the growth and proliferation of cancer cells. This makes it particularly effective in treating cancers with mutations in the BRAF gene, such as melanoma and colorectal cancer. By inhibiting these kinases, Lifirafenib disrupts the signaling pathways that promote tumor growth, leading to reduced cancer cell survival and proliferation. It is often explored in clinical trials to assess its efficacy and safety in combination with other anticancer agents, aiming to improve outcomes for patients with advanced or treatment-resistant cancers.